Human embryonic stem cell-derived cardiomyocyte platform screens inhibitors of SARS-CoV-2 infection. (2021)
Attributed to:
Phase 1 COVID-19 Immunity - National Core Study
funded by
COVID
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1038/s42003-021-02453-y
PubMed Identifier: 34326460
Publication URI: http://europepmc.org/abstract/MED/34326460
Type: Journal Article/Review
Volume: 4
Parent Publication: Communications biology
Issue: 1
ISSN: 2399-3642